The medicine, called Leqembi, slowed decline by 27 percent over 18 months compared with placebo, a study showed. But side effects and cost are fueling controversy.
FDA gives full approval to first drug to clearly, but modestly, slow Alzheimer’s
The medicine, called Leqembi, slowed decline by 27 percent over 18 months compared with placebo, a study showed. But side effects and cost are fueling controversy.